We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+5.05%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.58B
AUM Growth
+$636M
Cap. Flow
+$643M
Cap. Flow %
17.97%
Top 10 Hldgs %
40.4%
Holding
113
New
37
Increased
33
Reduced
14
Closed
23

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$210M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$166M
3
RGEN icon
Repligen
RGEN
+$118M
4
ARWR icon
Arrowhead Research
ARWR
+$87M
5
IMCR icon
Immunocore
IMCR
+$70.6M

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$191M
2
TERN
Terns Pharmaceuticals
TERN
+$144M
3
DXCM icon
DexCom
DXCM
+$84.6M
4
MRK icon
Merck
MRK
+$81.6M
5
TYRA icon
Tyra Biosciences
TYRA
+$76.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VCYT icon
76
Veracyte
VCYT
$3.61B
$4.21M 0.12%
+130,687
New +$4.84M
ZBIO
77
Zenas BioPharma
ZBIO
$1.97B
$3.91M 0.11%
+200,000
New +$4.49M
GERN icon
78
Geron
GERN
$821M
$3.78M 0.11%
2,540,000
-8,780,000
-78% -$13.3M
MNPR icon
79
Monopar Therapeutics
MNPR
$748M
$3.58M 0.1%
+65,418
New +$3.95M
ZURA icon
80
Zura Bio
ZURA
$524M
$3.04M 0.09%
+511,000
New +$3.09M
NVCR icon
81
NovoCure
NVCR
$1.78B
$2.73M 0.08%
250,000
-275,000
-52% -$3.43M
NYXH
82
Nyxoah
NYXH
$146M
$2.54M 0.07%
868,661
-238,339
-22% -$1.01M
URGN icon
83
UroGen Pharma
URGN
$1.88B
$2.5M 0.07%
+139,079
New +$2.79M
PASG icon
84
Passage Bio
PASG
$14.4M
$2.39M 0.07%
305,000
– –
TYRA icon
85
Tyra Biosciences
TYRA
$1.91B
$2.07M 0.06%
54,000
-2,371,000
-98% -$76.8M
RGNX icon
86
Regenxbio
RGNX
$638M
$909K 0.03%
108,525
+74,525
+219% +$783K
TENX icon
87
Tenax Therapeutics
TENX
$536M
$854K 0.02%
53,439
– –
MGNX icon
88
MacroGenics
MGNX
$243M
$809K 0.02%
280,000
– –
ABSI icon
89
Absci
ABSI
$1.34B
$697K 0.02%
+232,219
New +$672K
APRE icon
90
Aprea Therapeutics
APRE
$7.4M
$267K 0.01%
+350,000
New +$275K
ABT icon
91
Abbott
ABT
$185B
– –
-600,000
Closed -$75.2M
ACLX
92
DELISTED
Arcellx
ACLX
– –
-2,925,000
Closed -$191M
ALEC icon
93
Alector
ALEC
$168M
– –
-755,000
Closed -$1.18M
AXSM icon
94
Axsome Therapeutics
AXSM
$10.9B
– –
-210,000
Closed -$38.4M
BDTX icon
95
Black Diamond Therapeutics
BDTX
$99.7M
– –
-870,000
Closed -$2.11M
DAWN
96
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-5,200,000
Closed -$48.5M
DBVT
97
DBV Technologies
DBVT
$804M
– –
-300,000
Closed -$5.75M
DXCM icon
98
DexCom
DXCM
$32.9B
– –
-1,275,000
Closed -$84.6M
FATE icon
99
Fate Therapeutics
FATE
$291M
– –
-1,725,000
Closed -$1.69M
GILD icon
100
Gilead Sciences
GILD
$163B
– –
-50,000
Closed -$6.14M
1 2 3
4
5

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Vestal Point Capital held 113 positions worth $3.58B, up 22% from $2.94B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Vestal Point Capital deployed $643M of net new capital in Q1 2026, opening 37 new positions and adding to 33 existing holdings. Its largest new stake was Neurocrine Biosciences: 1,250,000 shares worth $165M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $144M trimmed.

  • Vestal Point Capital's largest Q1 2026 buy was Neurocrine Biosciences: 1,250,000 shares worth $165M.
  • Vestal Point Capital added most to Revolution Medicines in Q1 2026, an estimated $210M increase.
  • Vestal Point Capital's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $144M.
  • Vestal Point Capital fully exited Arcellx in Q1 2026, selling an estimated $191M.
  • Vestal Point Capital's ten largest holdings make up 40% of its $3.58B portfolio in Q1 2026.
  • Vestal Point Capital opened 37 new positions and closed 23 in Q1 2026.
  • Vestal Point Capital's portfolio value rose 22% quarter-over-quarter to $3.58B.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.